# US 2026/0076824 A1 · Baffle devices and related methods for delivery of therapeutic compositions to the eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076824 A1
- Document ID: US20260076824A1
- Status: Published application
- Kind: A1
- Application number: 19/179,544
- Filed: 2025-04-15
- Published: 2026-03-19
- Earliest claimed: 2024-09-17
- Assignees: D&D Biopharmaceuticals, Inc.
- Applicants: D&D Biopharmaceuticals, LLC
- Inventors: Bruce H. DeWOOLFSON; Michael LUTTRELL; Dale P. DeVORE
- Web page: https://patentgrep.com/patent/US20260076824A1

## CPC

- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Medical devices, e.g., baffle devices, and related methods of use to administer therapeutic compositions to the eye are described. The medical device may include a body defining a lumen and including an intermediate portion that includes a compressible bellows. The device may have a flared distal end configured to contact a convex surface of the eye.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating an eye of a subject, the method comprising:
placing a distal end of a medical device against a surface of the eye, wherein the device includes a body defining a lumen, the body comprising an intermediate portion that includes a compressible bellows, and wherein the distal end of the device forms a seal against the surface of the eye; and
introducing a therapeutic composition to the lumen to contact the surface of the eye, wherein the therapeutic composition comprises a retinal drug and a buffer solution;
wherein the device is off-center relative to a cornea of the eye when the therapeutic composition contacts the surface of the eye, such that the therapeutic composition contacts a sclera of the eye.

### Claim 22 (depends on 21)

The method of claim 21, wherein the retinal drug comprises bevacizumab, ranibizumab, ceftazidime, dexamethasone, aflibercept, fluocinolone, avacincaptad pegol, ocriplasmin, methotrexate, pegcetacoplan, triamcinolone, farcimab, or vancomycin.

### Claim 23 (depends on 21)

The method of claim 21, wherein placing the distal end of the device against the surface of the eye includes compressing a portion of the bellows while a remainder of the bellows is uncompressed or expanded.

### Claim 24 (depends on 23)

The method of claim 23, wherein an inner angle of the bellows in a neutral position ranges from about 45 degrees to about 75 degrees, and wherein the portion of the bellows is compressed relative to the neutral position while contacting the surface of the eye.

### Claim 25 (depends on 21)

The method of claim 21, wherein the subject has keratoconus and the distal end of the device accommodates a conical shape of the surface of the eye to form the seal.

### Claim 26 (depends on 21)

The method of claim 21, wherein the subject has astigmatism, and the distal end of the device accommodates an irregular shape of the surface of the eye to form the seal.

### Claim 27 (depends on 21)

The method of claim 21, wherein a wall thickness of the bellows ranges from about 0.01 cm to about 0.1 cm.

### Claim 28 (depends on 21)

The method of claim 21, wherein the therapeutic composition contacts the surface of the eye for about 30 seconds to about two minutes.

### Claim 29 (depends on 21)

The method of claim 21, wherein the distal end of the device flares radially outward.

### Claim 30 (depends on 21)

The method of claim 21, wherein the therapeutic composition further comprises an acylating agent.

### Claim 31 (depends on 21)

The method of claim 21, further comprising administering an acylating agent to the surface of the eye before introducing the therapeutic composition.

### Claim 32 (depends on 21)

The method of claim 21, further comprising coupling a proximal end of the medical device to a handle component before placing the distal end of the medical device against the surface of the eye.

### Claim 33 (depends on 32)

The method of claim 32, wherein the handle component includes a ridge or a groove complementary to a respective groove or ridge of the medical device.

### Claim 34 (depends on 21)

The method of claim 21, further comprising coupling a proximal end of the medical device to a cartridge before placing the distal end of the medical device against the surface of the eye.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cartridge includes a ridge or a groove complementary to a respective groove or ridge of the medical device.

### Claim 36 (depends on 34)

The method of claim 34, wherein the cartridge is preloaded with the therapeutic composition.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cartridge is sealed while coupling the proximal end of the medical device to the cartridge.

### Claim 38

A method of treating an eye of a subject, the method comprising:
coupling a proximal end of a medical device to a cartridge, wherein the device includes a body defining a lumen, the body comprising an intermediate portion that includes a compressible bellows, and wherein the cartridge is preloaded with a therapeutic composition that comprises an active agent and a buffer solution;
placing a distal end of the medical device against a surface of the eye to form a seal against the surface of the eye; and
expelling the therapeutic composition from the cartridge into the lumen to contact the surface of the eye;
wherein placing the distal end of the device against the surface of the eye includes compressing a portion of the bellows while a remainder of the bellows is uncompressed or expanded.

### Claim 39 (depends on 38)

The method of claim 38, wherein the device is off-center relative to a cornea of the eye when the therapeutic composition contacts the surface of the eye, such that the therapeutic composition contacts a sclera of the eye.

### Claim 40 (depends on 38)

The method of claim 38, wherein the active agent is a retinal drug.
